Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge. In this report, we have investigated the immunological and cellular mechanisms underlying the induction of dormancy. BCL1 tumor cells were injected into SCID mice passively immunized with antibody against different epitopes on IgM or IgD with or without idiotype (Id)-immune T lymphocytes. Results indicate that antibody to IgM is sufficient to induce a state of dormancy. Antibodies against other cell surface molecules including IgD and CD44 (Pgpl) had no effect on tumor growth. Id-immune T cells by themselves also had no effect on tumor growth in SCID mice. However, simultaneous transfer of anti-Id and Id-immune T cells enhanced both the induction and duration of the dormant state. In vitro studies indicated that antibody to IgM induced apoptosis within several hours and cell cycle arrest by 24 h. Hyper cross-linking increased apoptosis. The FcqcRII receptor played little or no role in the negative signaling. Antibodies that did not negatively signal in vitro did not induce dormancy in vivo. The results suggest that anti-IgM plays a decisive role in inducing tumor dormancy to BCL1 by acting as an agonist of IgM-mediated signal transduction pathways.
C
ancer dormancy is a well-recognized clinical phenomenon in which tumor cells are present but the population does not increase for long periods of time. However, tumor cells can regrow many years or even decades later. Cancer dormaney therefore represents an important clinical problem. At a basic level, it is also intriguing that malignant cells (characterized by uncontrolled growth) can survive for decades in vivo without apparent expansion of the cell population.
In an effort to gain more insight into the mechanisms underlying tumor dormancy, we have used a well-characterized B cell lymphoma, BCL11 (1, 2) , in mice immunized with the BCL1 idiotype-positive (Id +) IgM (3) . We have shown that the major outcome of such immunization and challenge 1 Abbreviations used in this paper: BCL1, B cell lymphoma; CCA, cell cycle arrest; DLC, dormant lymphoma cell; GAILIg, goat anti-rabbit IgG; Id § idiotype positive; MA BCL1 Id, polyclonal mouse anti-BCL1 Id; MARK, mouse anti-rat g; MFI, mean fluorescence intensity; R.tAM)~, rat anti-mouse X; RtAM~, rat anti-mouse ~; tLAGM1, rabbit anti-asialo GM1; 7-AAD, 7-amino actinomydn D.
is a state of dormancy in which dormant lymphoma cells (DLC) persist in stable numbers for the 200 d of observation and are maintained in the majority of animals throughout life as evidenced by cell transfer experiments (4, 5) . Isolation of DLC by multiparameter flow cytometry indicates that they are different from the growing BCL1 cells with regard to size, morphology, and cell cycle status. We therefore suggested that signals induced by cross-linking of mlg with antibodies to BCLt Id are responsible for the induction and maintenance of the dormant tumor state.
In the present studies, we have explored the roles of anti~ IgM, anti-IgD, and Id-specific T cells in inducing tumor dormancy by passively immunizing SCID mice. We have also analyzed the mechanisms underlying the antibody-induced dormant state by use of an in vitro-adapted cell line derived from the BCLt tumor (designated BCL1 3B3) (6) . We present evidence that anti-# antibodies act as agonists rather than via conventional effector mechanisms to induce and maintain tumor dormancy. They do this by inducing both apoptoffs and cell cycle arrest (CCA). Anti-IgM but not anti-IgD induces these antitumor effects and the Fc'yRII plays little or no role. Id-specific T cells cannot by themselves induce dormancy, but they synergize with anti-IgM to induce a more long-lived dormant state.
Materials and Methods
BCLI 3B3 Tumor. The BCL1 tumor and its 3B3 subline were maintained in vivo by i.v. and i.p. passage in BALB/c or SCID mice. 5 wk after inoculation of 5-10 x 105 spleen cells from a tumor-bearing animal, mice were killed and their splenocytes were used as a source of tumor cells. Alternatively, BCL1 3B3 cells were maintained in vitro and 3 x 104 cells were injected directly into each SCID mouse. Tumor cells in the spleens of dormant mice were determined by flow cytometry and by adoptive transfer of graded numbers of splenocytes from dormant mice into naive BALB/c mice. Splenomegaly was determined by palpation as previously reported (4) .
BCLI Id-KLH Conjugation and Immunization. Conjugation of
the Id § BCL~ IgM to KLH and the immunization of BALB/c mice have been described previously (4) .
Antibodies. Hybridoma cells secreting rat IgG2a anti-BCL~ Id
(KtA Id) (6A5) were a gift from Dr. Freda Stevenson (Southampton, UK). The Id § IgM~, was purified from the ascites of C5D5 hybridoma which was generated by fusing BCL~ cells with SP2/0 myeloma cells (7) . Rat anti-mouse ~, (RtAMh) (B1.1) was generated in our laboratory and previously described (8) . Rat anti-mouse r (RtAMS) (JA12.5) was produced by Abbott Biotech, Inc. Normal rat IgG (NRt IgG) and normal mouse IgG (MIgG) were prepared from pooled normal sera by chromatography on Sephadex A-50. Rat anti-mouse CD44 (IM7) (KtAM CD44), RtAMr (JA 12.5), and rat anti-mouse IgM (RtAM#) (Bet-2) were purified from the supernatants of hybridomas obtained from the American Type Culture Collection (Rockville, MD). Polyclonal mouse anti-BCL~ Id (MA BCL1 Id) ascites was produced by intraperitoneal injection of pristane into Id-immune mice followed 1-2 wk later by intraperitoneal injection of SP2/0 myeloma cells. Polyclonal rabbit anti-BCL1 Id (RA BCL1 Id), rabbit anti-mouse # (RA/.t), rabbit antiovalbumin (KAOVA), goat anti-mouse ~5 (GAr goat anti-mouse # (GA/~), goat anti-ovalbumin (GAOVA), and goat anti-rabbit IgG (GARIg) were produced and affinity purified as previously described (2) . Aggregation of RAOVA was performed by heating it at 60~ for 10 min until the solution became slightly turbid. Hoechst. Cell doublets and large aggregates were excluded from the analysis using appropriate gating on pulse process signals from the Hoechst emission (signal width vs. area). Apoptotic cells were identified as above except that cells were stained with 400/zM 7-amino actinomycin D (7-ADD) (Molecular Probes, Inc., Eugene, OR) in PBS at 4~ for 30 min before fixation (9) . For tumor cells from spleens of BCLl-bearing mice, splenocytes were stained for surface markers using RtAM)~ and FITC-MARK with or without additional PE-conjugated antibodies, stained with 7-AAD and Hoechst, and analyzed as described above.
Flow cytometry data were analyzed by "Paint-a-Gate" software as described (10) . This analysis enables a multi-dimensional identification of cells reactive with the antibodies as well as the determination of their relative sizes (small vs. large) based on the position of the cells in the correlative display of forward vs. orthogonal light scattering. A magnet was attached to the bottom of the flask and the cells were incubated for 10 min at room temperature. The flask was gently inverted, decanted, an additional 0.7 ml beads was added, and the procedure was repeated. The depleted cells were then pelleted, pooled, and resuspended at 10 s per ml. Alternatively, spleen cells with lysed RBCs were adjusted to 1.5-2 x 10 s cells/ml and B cells and Fc~/RII § cells were removed by use of mouse T cell enrichment columns. Cells from each spleen were purified on a single column. Aliquots of cells were sampled before and after both purifications and the numbers of B and T cells were determined by FACS | analysis. The two methods gave similar results.
Agarose Gel Electrophoresis of DNA. 107 cells were treated with proteinase K (1 mg/ml) in 50 mM Tris-HC1, pH 8.0/100 mM NaC1/100 mM EDTA/1% SDS, and the DNA was isolated by phenol/CHC13, 1:1 (vol/vol) extraction and ethanol precipitation. DNA isolated from 3 x 105 cell equivalents was treated with RNase A (1 mg/ml) and resolved in 2% agarose gels with lx TAE buffer (40 mM Tris acetate, 2 mM EDTA) (11) .
Elimination of NK Cells from SCID Mice. Rabbit anti-asialo GM1 (RAGM1) (Wako Pure Chemical Industries, Inc., Osaka, Japan) was used to eliminate NK cells from SCID mice. 25/zl of this antibody was calibrated by Wako and found to diminish NKmediated killing of YAC-1 at an E/T ratio of 50:1 by 97% when injected into mice. 25 gtl of this antibody was injected into SCID mice and the NK activity was measured by lung clearance of 12sI-UdR-labeled YAC-1 cells as previously described (12) . A sixfold reduction in NK function was demonstrated in the SCID mice treated with RAGM1.
Results

Antibody-induced Dormancy in SCID BCLI
Mice. The capacity of antibody to induce dormancy in the absence of BCLl-specific cytotoxic T cells was studied by passive immunization of SCID mice. A series of polyclonal and monoclonal antibodies specific for various epitopes on Ig were injected into the mice before injection of BCL1 or BCL1 3B3 cells. Dormancy was defined as the absence of splenomegaly at 60 d since in virtually all control mice, splenomegaly was detected by 35-45 d after challenge with BCL1 or BCLl 3B3 cells. As shown in Table 1 , 53-79% of BCLt-inoculated mice developed dormancy depending upon the particular antiIg antibody used. The polyclonal antibodies were more effective as judged by the duration of dormancy. Essentially similar results were obtained using BCL1 3B3 cells (Table 2) except that the tumor cells grew slightly faster (controls had splenomegaly by 25-35 d) and the incidence of dormancy was lower and duration shorter than those observed when the parent BCL1 tumor cells were used (data not shown).
When the spleens from dormant SCID/BCL~ mice injected with BCL1 3B3 were stained with RtAMX and examined by flow cytometry, DLC were identified by staining with anti-X (Fig. 1 ). These cells represented 0.1-1% of the spleen cells and were few in number ("~10 s DLC) because of the small size of the SCID mouse spleens and because only 3 x 104 BCLt 3B3 cells were inoculated. In the 66 mice We considered the possibility that the role of antibody was to divert the tumor cells from the spleen to another organ and/or to deplete them by Fc-mediated effector mechanisms, e.g., opsonization or ADCC. To test these possibilities, RtAM CD44 and RtAM~, were administered to SCID mice challenged with BCL1 3B3 ceils. These antibodies bind to BCL1 3B3 cells without affecting their growth in vitro. Mice treated with these antibodies showed no antitumor immunity. GAg, which has little or no affinity for the FcyRII (13), was highly effective in inducing dormancy. In addition, when mice were first injected with BCL1 cells and 3-7 d later with anti-# (to allow the tumor cells to home to the spleen before treatment with antibody) antibody was completely effective 3 d and moderately effective 1 wk after BCL1 chaUenge, despite the 3-7 d of tumor growth before treatment (anti-# injected at -1, + 3, and + 7 d later showed dormancy in six of nine, four of five, and three of five mice, respectively). These results make it unlikely that anti-Ig diverts the tumor cells to another anatomical site.
SCID mice lack T and B ceils but have normal or above normal levels of NK cells (14) . To test the possibility that NK cells contributed to the induction of dormancy, SCID mice were treated with 25 #1 of RAGM1 antibody 3 d before injection of BCL1 cells and 4 and 11 d thereafter. A single injection of 25/zl of RAGM1 reduced NK function in SCID mice more than sixfold. MA BCL1 Id was injected on day 1 and weekly thereafter for 7 wk. The results demonstrated that RAGM1 had no significant effect on the ability of MA BCL1 Id to induce dormancy. Anti-asialo GM1 injected with anti-# induced dormancy in four of five mice (average of 84 _+ 15 d before splenomegaly appeared); injection of anti-# alone induced dormancy in five of five mice (average 91 _+ 13 d before splenomegaly appeared). This suggests that antibody-mediated effector mechanisms do not contribute to the induction of dormancy in a major way, and this result is consistent with our working hypothesis that the antitumor effects of MA BCL~ Id are caused by signal transduction.
The Effect of Id-immune T Cells on Dormancy in SCID
Mice. In prior experiments using SCID mice injected with antibody and challenged with BCL1 3B3 or BCL1 cells, the duration of dormancy was usually less than that previously reported for BALB/c Id-immune mice (3, 5, 15) . A possible explanation is that Id-specific T cells contribute to the induction and maintenance of dormancy. Therefore, Id-immune T cells were injected into SCID mice with or without antiId to determine if T cells had any role in the induction of dormancy. To facilitate the detection of an additive effect by Id-immune T cells, SCID mice were treated with suboptimal doses of MA BCL1 Id, which alone induced dormancy in 
Effect of Polyclonal Antibodies on [3H]Tkymidine Incorporation in BCLI 3B3 Cells In Vitra
To analyze the mechanisms underlying the induction of dormancy, in vitro, studies using BCL1 3B3 were undertaken. Fig. 2 demonstrates that polyclonal antibodies proven to induce dormancy of BCL1 3B3 in SCID mice (see Table 2 ) also significantly reduced [3H]thymidine incorporation in BCL1 3B3 cells in vitro. R.tAM CD44 and B, tAM8 antibodies that were ineffective in vivo had no effect on thymidine incorporation in vitro (to be discussed below).
The reduction in [3H]thymidine incorporation induced by RA BCL1 Id is related to receptor occupancy (Fig. 3) . Receptor occupancy was measured by determining the mean fluorescence intensity (MFI). As can be seen, MFI reached a plateau at 1/zg/106 cells at which point [3H]thymidine incorporation diminished incrementally up to the highest concentration used (8/~g/106 cells). The continued decrease in [3H]thymidine uptake after saturation of surface IgM (mlgM) could be explained by continued cross-linking of newly expressed mlgM molecules when an excess of anti-Id was present. It is unlikely that dissociation of antibody from mlgM could account for this finding since hyperimmune polyvalent antibodies (which have a high affinity and low rate of dissociation) were used. These results indicate that antibodies that induce dormancy in vivo, have antiproliferative effects in vitro and that these effects occur when receptor occupancy is complete and continued for many hours.
Cell Cycle Arrest and Apoptosis Are Induced by Cross-linking IgM.
The above experiments demonstrate that anti-/~ or anti- Id antibodies induce antiproliferative activity in BCL~ 3B3 cells. To determine the cellular mechanisms underlying this inhibition, treated cells were analyzed by flow cytometry for cell permeability (death) vs. DNA content (cell cycle). As shown in Fig. 4 , 45% of the BCL1 3B3 cells treated with RAp were dead as compared to 3.3% of the RAOVA-treated cells. Cell death was a result of apoptosis, since gel analysis of DNA from treated cells revealed the typical nucleosomal ladder (data not shown). The RAp-treated cells also showed a marked decrease in the proportion of viable cells in S, G2, and M phases of the cell cycle as compared to RAOVA-treated cells (9.3% vs. 24.3%, respectively) (Fig. 4) . To prove that the decrease in the proportion of cycling cells was due to CCA, cells were treated with vinblastine which inhibits mitosis by interacting with the microtubular protein, tubulin (16) . If cells are arrested in G0/G1, then the observed increase in the G0/gl fraction will be maintained after vinblastine treatment, whereas if the cells are cycling more slowly as a result of anti-Id treatment, then the G0/G1 fraction will decrease as the cells progress to the block in mitosis. In these experiments, cells (17) (18) (19) (20) (21) (22) (23) . We investigated the kinetics of induction of CCA and apoptosis by flow cytometry. Fig. 6 represents a compilation of four experiments in which cell death and CCA were induced with RA BCL1 Id. Loss of membrane integrity and DNA degradation in apoptotic cells was detectable as early as 2 h after treatment and their percentage continued to increase throughout the time course of 24 h. In contrast, CCA was not detectable until 8 h after antibody treatment and increased in the residual viable cells at 24 h. These results indicate that a poruon (or all) the cell death observed can occur independently of CCA. These findings are consistent with the existence of at least two partially independent signal transduction pathways in BCL1 3B3 cells after mlg cross-linking, that is, one leading directly to apoptosis/necrosis and one leading to CCA (11) . (25, 26) . In the first series of experiments, we demonstrated that F(ab')2 fragments of goat or rabbit antibody were highly effective at inducing CCA and apoptosis in vitro. Goat F(ab')2 was as effective as goat IgG (Fig. 8 A) , however, F(ab')2 fragments of rabbit IgG were slightly less effective than the rabbit IgG antibody in vitro (data not shown). This could be due to the ,o17% decrease of the binding affinity of the rabbit F(ab')2 compared to the intact antibody. Therefore, further experiments were carried out to block the coligation of the Fc'yKII with crosslinked Ig. As shown in Fig. 8 B, blocking the Fc receptor by pretreating the cells with nonaggregated or heat-aggregated RAOVA before the addition of RA# had no effect on the capacity of RA# to inhibit thymidine incorporation. Taken together, these data indicate that the FcTKII does not contribute significantly to the inhibitory signal induced by cross-linking mlgM.
The Effect of "Hyperaggregation
Effect of Anti-8 on the Induction of Dormancy.
There are contradictory reports indicating whether cross-linking IgD can induce an inhibitory signal (24, 27, 28) . One study suggested that although anti-/~ by itself cannot induce a negative signal in WEHI231 cells, it can increase the negative signaling induced by anti-# antibodies (28) . We, therefore, performed several experiments to determine the role of IgD signaling in BCLa 3B3 cells. Polyclonal (goat) or monoclonal (rat) anti-~ antibodies at various concentrations (2-500 #g) had no effect on 3 x 104 BCLt 3B3 cells in vitro. Moreover, there was no increase in inhibition observed when a constant suboptimal dose of tLA/z (1.75 #g/ml) was compared to the same dose of anti-/z administered simultaneously with increasing doses of polyclonal or monoclonal anti-~ antibodies. Thus, there was no evidence that negative signaling could occur through IgD. However, although all the 3B3 cells stained with monodonal rat anti-~, the density of mlgD was only 10% that of mlgM as determined by MFI using FITC-labeled MARK. Hence, we cannot exclude the possibility that the negative result would be due to the low density of mlgD.
Anti-/.t Treatment of BCLI 3B3 Cells Growing in SCID Mice.
To determine what roles cell death and CCA play in inducing dormancy, SCID mice were injected with 106 BCL1 3B3 ceils and palpated weekly for splenomegaly. When the spleen enlarged to a size consistent with the presence of 5 x l0 s tumor cells, mice were injected with a single dose of 500/zg of RA# or GA# or their respective control antibodies. After 24 and 48 h, animals were killed, the spleens were removed, and splenocytes were analyzed by flow cytometry for cell death and CCA. Cells were also lysed and analyzed by agarose gel electrophoresis for DNA fragmentation. When GA/z antibodies (Fig. 9 A) were injected, 4.1% of the ceils were dead at 24 h and 30.8% were dead at 48 h. Cell death after treatment with KA/Z peaked at 24 h with 62.5% dead cells vs. 3.6% after RAOVA treatment (Fig.  9 B) . By 48 h, RA#-treated cells had only 7.9% more dead cells than the controls (14.4 vs. 6.5%). The sharp decline in the proportion of dead ceils is probably related to rapid cell lysis and clearance of dead cells by the host. Agarose gel analysis for DNA laddering was performed on the aliquots of cells used for flow cytometric analysis (Fig. 9 C) . The results demonstrate the presence of nucleosome multimersized fragments only in the cells removed from mice treated with GA/Z after 48 h and RA/z after 24 h. Thus, a portion, if not all of the GA#-or KA/z-induced cell death of BCL1 3B3 ceils results from signal-induced apoptosis. These experiments suggest that signal-induced cell death is an important mechanism contributing to induction of dormancy. In the mice in which apoptosis was induced by anti-/z, there appears to be CCA as well (Fig. 9, A and B) . However, there is considerable variation in the proportion of cycling cells in control mice so that a much larger number of control and anti-/z-treated mice will have to be studied before a conclusion can be reached.
Discussion
The major findings to emerge from this study are: (a) Antibodies directed against a variety of epitopes on mlgM induce tumor dormancy in a proportion of SCID mice chal- Taken together, the in vivo and in vitro data suggest that signal transduction rather than classical immunological effector functions are the major contributors to tumor dormancy. This conclusion is based on the following observations: (a) There is a strict correlation between the capacity of antibodies to induce negative signaling in vitro and their ability to induce dormancy or, indeed, to have any affect on tumor growth in vivo. Thus, RtAMt5 and RtAM CD44 that bind to BCL1 3B3 cells were ineffective, whereas RA/z, RA BCL1 Id, and RtAMX were effective. These results are consistent with a growing body of evidence indicating that antibodies against surface molecules associated with the Ig signaling complex have powerful antitumor effects and that these are due to their signaling properties. Thus, lymphoma regression induced by monoclonal anti-Id antibodies correlates with their ability to induce an increase in tyrosine phosphorylation in vitro (29) . Both anti-CD19 (30) and anti-CD20 (31) inhibit the growth of human lymphoma cells in SCID mice. Of particular importance, the F(ab')2 fragment of anti-CD19 is as effective as intact antibody in preventing tumor growth, proving that its antitumor activity is not due to Fc-mediated effector mechanisms (30) . The ability of anti-CD19 to induce CCA in B lymphoma lines in vitro is consistent with this conclusion (11, 30) . Anti-CD21, anti-CD23, and anti-CD24 can downregulate the growth of EBV-positive B cell lymphomas in SCID mice (32) and in humans (33) , although the mechanisms responsible have not been explored. Anti-CD81 has antiproliferative activity in B cell lymphomas (34) . Recent studies have shown that anti-CD40 can inhibit the growth of B cell lymphomas in vitro (35, 36) and display antitumor activity in SCID/ lymphoma mice; the mechanisms have not been elucidated. We have obtained similar results using anti-CDS, -CD20, and -CD21 in vitro (Vitetta, E. S., and J. W. Uhr, unpublished data). It is not surprising that the therapeutic potential of the signaling function of mAbs has not been previously appreciated. Thus, mAbs selected for therapeutic use were selected on the basis of their specificity for tumor cells and their effector function (37) (38) (39) (40) . They were not screened in vitro for negative signaling which may be the major contributor to their antitumor effects.
In contrast to antibodies, Id-specific T cells by themselves were unable to induce dormancy under the conditions of our experiments. However, when Id-specific T cells were administered with anti-BCLl Id antibody, they synergized in the induction and maintenance of dormancy. This could be due to the secretion of cytokines or cytotoxic T cell activity. Cytokines released from T cells could increase the CCA or apoptosis mediated by anti-Ig. If CTLs are involved, then the intracellular pathway used may increase the proportion of tumor cells undergoing apoptosis since cytotoxic T cells can also induce this effect on target cells (41) .
There is accumulating information on the molecular events underlying the capacity of anti-# to induce CCA and apoptosis by cross-linking surface IgM in B lymphoma cells and in immature B lymphocytes. The present concept of B cell signaling (reviewed in 42, 43) is that cross-linking of IgM initiates the phosphorylation of the Igot and ~ chains, that one or more of the src family kinases, Lyn, Fyn, Lck, and Blk, then bind to docking sites on the phosphorylated Igor and/~ chains, that this interaction activates the kinases which, in turn, leads to phosphorylation of a set of cytoplasmic proteins, possibly including another tyrosine kinase, Syk. PLC3, is activated resulting in generation of inositol triphosphate and diacylglycerol. Intracellular Ca § § levels are elevated and, in turn, protein kinase C is activated. A series of second messengers that are serine/threonine kinases are phosphorylated by pathways that have not been clarified. Eventually there is activation of transcription regulators such as c-fos, jun B, erg, and other early proteins. The result is activation and differentiation of mature B cells.
Although there are many similarities in the physiological changes associated with activation of mature B cells and negative signaling in B lymphoma cells, there are differences between the biochemical events in these two cell types. Thus, coligation of the Fcq, RII with membrane Ig in a normal B cell or a B cell tumor that cannot be negatively signaled results in a dominant negative effect, that is, the activation by crosslinking IgM can be overridden by coligation of Fcq, RII (25) . This effect of Fcq, RII has been shown to be dependent on exogenous calcium ions (26) . In contrast, in the BCL1 3B3 cell line, neither coligation of Fcq, RII with IgM nor the absence of extracellular Ca 2+ ion (data not shown) significantly affects negative signaling. Another feature that distinguishes signaling in the two cell types is the role of IgD. Cross-linking IgD on normal B lymphocytes results in activation (44) . Cross-linking IgD by itself or together with IgM on BCL1 3B3 cells does not affect signaling. Finally, as indicated above, positive signaling results in replication and differentiation, whereas negative signaling causes CCA and apoptosis. Hence, although portions of the signaling pathways in activated mature B cells and growth inhibited B lymphoma cells are probably identical, there must be differences in the pathways from the cell surface to the transcriptional response that remain to be characterized. These could depend on inherent differences between the two cell types.
There is also evidence that the signaling pathways involved in CCA and apoptosis may be partially independent. We have reported that antisense oligonucleotides targeted to the lyn gene prevent induction of CCA, but not apoptosis resulting from cross-linking surface IgM on murine or human lymphoma cells (11) . This finding suggests that there is a bifurcation point depending on Lyn that separates the two pathways. In contrast, experiments with antisense bile suggests that this PTK is essential for induction of apoptosis (21) .
What is the relationship between signaling lymphoma cells to undergo CCA and death and signaling their normal cellular counterparts with physiological ligands? The simplest explanation is that the stimuli and signaling pathways are identical. There is a large body of evidence to suggest that after contact with antigen, CCA and apoptosis can occur in immature B cells and in mature B cells if no accessory signals are concurrently received (18, 45) . These cellular events have been implicated in the induction of anergy (45, 46) and clonal deletion of self-reactive cells (47) leading to B cell tolerance.
There are several arguments to suggest that the signaling described here may be abnormal. Thus, it is unlikely that physiological concentrations of self antigens (particularly those in low concentrations) are sufficient to occupy all the specific receptors on B cells. Many self antigens may be paucivalent or even univalent and might not be effective at extensive crosslinking even when presented on a cell surface. Also, the L and H chain variable genes of naive B cells have not yet undergone hypermutation. Hence, their slg will have a relatively low binding affinity for self antigens. Thus, it is likely that lesser degrees of cross-linking are sufficient to negatively signal B cells. In contrast, the use of anti-Ig antibodies (particularly polyclonal ones) saturate and cause massive clustering of these receptors. There is abundant literature to suggest that hyper cross-linking can increase negative signaling and in the present studies, apoptosis (24) . Thus, increasing haptenization of proteins can render them more tolerogenic (48, 49) . Using fluorescence photobleaching to measure lateral diffusion of surface Ig receptors, it has been observed that there is a relationship between the increase in the fraction of mobile surface Ig receptor aggregates and the induction of B cell tolerance (50) . It has recently been shown that immobilization of anti-/~ or anti-~5 antibodies on plastic can induce apoptosis in mature B cells (51) . This is not the normal response of B cells to specific soluble antigens or, indeed, to soluble anti-IgD. We speculate, therefore, that antibodymediated signaling of tumor cells may be different from physiological signaling, either in quantity (It is possible that during development, concentrations of physiological ligands are markedly increased in order to induce apoptosis in particular cell lineages and in that sense are physiological.) or quality. Hyperaggregation of large numbers of cell surface molecules could significantly alter the architecture of the plasma membrane or its underlying structures to such a degree that physiological signaling cascades are disrupted. This might result in apoptosis or CCA in normal or malignant cells. This does not exclude the possibility that tumor cells may be more susceptible than normal cells to such negative signaling.
Regardless of the mechanisms, these considerations have implications for clinical intervention. Thus, super cross-linking could be enhanced by the generation of multivalent antibodies using recombinant DNA technology. These could be multispecific against different epitopes on the same molecule or, indeed, on different molecules to achieve hyper cross-linking. If this approach is proved effective in inducing apoptosis, it might be useful in eliminating undesired cells, that is, autoimmune B or T cells as well as neoplastic ones.
